Mn Services Vermogensbeheer B.V. raised its holdings in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 2.4% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 12,772 shares of the biopharmaceutical company’s stock after acquiring an additional 300 shares during the quarter. Mn Services Vermogensbeheer B.V.’s holdings in Regeneron Pharmaceuticals were worth $5,160,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Icon Wealth Partners LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at about $112,000. Signaturefd LLC boosted its position in shares of Regeneron Pharmaceuticals by 123.8% in the 2nd quarter. Signaturefd LLC now owns 358 shares of the biopharmaceutical company’s stock valued at $124,000 after purchasing an additional 198 shares during the period. Flagship Harbor Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at about $159,000. Ingalls & Snyder LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at about $204,000. Finally, Gilman Hill Asset Management LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at about $212,000. 66.06% of the stock is owned by hedge funds and other institutional investors.
REGN has been the subject of a number of research analyst reports. Leerink Swann upped their target price on Regeneron Pharmaceuticals from $506.00 to $512.00 and gave the company an “outperform” rating in a research report on Monday, October 1st. ValuEngine raised Regeneron Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Thursday, September 6th. BidaskClub raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, September 1st. Morgan Stanley upped their target price on Regeneron Pharmaceuticals from $409.00 to $412.00 and gave the company an “equal weight” rating in a research report on Thursday, October 11th. Finally, Argus upped their target price on Regeneron Pharmaceuticals from $383.00 to $415.00 and gave the company a “buy” rating in a research report on Monday, July 16th. Two equities research analysts have rated the stock with a sell rating, seventeen have given a hold rating and seven have given a buy rating to the stock. Regeneron Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $410.95.
Regeneron Pharmaceuticals stock opened at $357.61 on Wednesday. Regeneron Pharmaceuticals Inc has a twelve month low of $281.89 and a twelve month high of $432.50. The company has a quick ratio of 2.92, a current ratio of 3.62 and a debt-to-equity ratio of 0.10. The company has a market cap of $38.10 billion, a price-to-earnings ratio of 26.67, a P/E/G ratio of 1.18 and a beta of 1.34.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Tuesday, November 6th. The biopharmaceutical company reported $5.87 earnings per share for the quarter, topping analysts’ consensus estimates of $4.94 by $0.93. Regeneron Pharmaceuticals had a return on equity of 29.30% and a net margin of 25.65%. The company had revenue of $1.66 billion during the quarter, compared to analysts’ expectations of $1.64 billion. During the same period last year, the firm earned $3.99 EPS. The firm’s revenue for the quarter was up 10.8% on a year-over-year basis. As a group, research analysts forecast that Regeneron Pharmaceuticals Inc will post 19.31 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Mn Services Vermogensbeheer B.V. Has $5.16 Million Stake in Regeneron Pharmaceuticals Inc (REGN)” was originally reported by Week Herald and is owned by of Week Herald. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://weekherald.com/2018/11/07/mn-services-vermogensbeheer-b-v-has-5-16-million-stake-in-regeneron-pharmaceuticals-inc-regn.html.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Further Reading: Do You Need a Fiduciary?
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.